AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04952766 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples
Description: Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)
Study NCT05015803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
Study NCT06385873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
Study NCT06385873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
Study NCT06385873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
Study NCT06385873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA >1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
Study NCT04682808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-338
Description: FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
Study NCT04706520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Beverage Consumption
Description: All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
Study NCT04706520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study Beverage Consumption
Description: All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
Study NCT06493370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid/vitamin C
Description: A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
Study NCT04572347 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: It is an observational study, and no intervention will be provided.
Study NCT04959721 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection with triamcinolone acetonide, bupivacaine, and normal saline
Description: Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast.
Study NCT04191902 — intervention group
Intervention type: BEHAVIORAL
Intervention: orientation
Description: patients will be oriented
Study NCT05718908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Food supplement
Description: FibrofixPlus® is an authorized food supplement.
Study NCT00893490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve (AGV)
Description: AGV implantation
Study NCT00893490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: 3 minute MMC application
Study NCT00893490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amniotic membrane coverage
Description: single layer coverage of amniotic membrane
Study NCT04885816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon (DEB)
Description: Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter.
Study NCT04885816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stents (DES)
Description: Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines.
Study NCT05420818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversalis Fascia Inversion
Description: This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
Study NCT05323305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided regional block
Description: Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
Study NCT05284045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detailed information
Description: Subjects in this arm will receive usual information + detailed information on side effects
Study NCT05720832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WINGS-IP1 Smartphone Application
Description: The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content.
Study NCT05040217 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-BDNF Gene Therapy
Description: AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
Study NCT05040217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-BDNF Gene Therapy
Description: Gene therapy is a biological therapy delivering the BDNF gene to the brain
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent Meningococcal B Vaccine
Description: Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine MenB
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Study NCT04825223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Study NCT06301165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC induction chemotherapy
Description: TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
Study NCT06301165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP induction chemotherapy
Description: GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
Study NCT06074926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Associative Conditioning
Description: There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
Study NCT06074926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated Exposure
Description: There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
Study NCT04922593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010; paliperidone palmitate
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study NCT04922593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INVEGA SUSTENNA
Description: INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
Study NCT05873387 — intervention group
Intervention type: DEVICE
Intervention: Use of Eko DUO stethoscope (paired ECG/PCG)
Description: Auscultation of heart sounds using electronic stethoscope
Study NCT05795933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
Study NCT05235529 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Surgery replacement od the aortic valve
Study NCT05235529 — intervention group
Intervention type: DEVICE
Intervention: TAVI
Description: Transcatheter aortic valve implantation
Study NCT05225272 — intervention group
Intervention type: OTHER
Intervention: Enhanced Recovery Program for on-pump cardiac surgery
Description: Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
Study NCT06566807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib, obinutuzumab
Description: orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
Study NCT06073873 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: According to local product label
Study NCT03925116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COntraceptive pathway
Description: alternative way of aiding patients in deciding contraception method
Study NCT05631652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillSense System
Description: The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
Study NCT04865094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber
Study NCT04865094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06567184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Hearts Urban
Description: A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
Study NCT06567951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
Study NCT06557473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: 1.5mg/kg IV for induction of GA
Study NCT06557473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl IV 2 µg/kg for GA induction
Study NCT06566859 — intervention group
Intervention type: OTHER
Intervention: NRS 0. hour
Description: Numerical rating scala
Study NCT06566859 — intervention group
Intervention type: OTHER
Intervention: NRS 6. Hour
Description: Numerical rating scala
Study NCT06566859 — intervention group
Intervention type: OTHER
Intervention: NRS 12. Hour
Description: Numerical rating scala
Study NCT06566859 — intervention group
Intervention type: OTHER
Intervention: NRS 24. Hour
Description: Numerical rating scala
Study NCT05217368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandala painting
Description: In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
Study NCT05880537 — intervention group
Intervention type: OTHER
Intervention: Nexeon Arterial Venous Allograft
Description: Nexeon AVX allograft for hemodialysis access in end stage renal disease
Study NCT05553028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computerised tomography
Description: Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
Study NCT05553028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computerised tomography
Description: Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
Study NCT05217368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antenatal education
Description: Routine antenatal education will be given.
Study NCT05298215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
Study NCT05298215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline solution
Description: sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
Study NCT05405478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
Study NCT05405478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SNOT22 score
Description: score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
Study NCT06572527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children.
Study NCT05383677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anifrolumab
Description: Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Study NCT05383677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Study NCT05852444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Activation
Description: Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
Study NCT05852444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Dynamic Agitation
Description: Agitation of root canal irrigation solution with master gutta percha cone
Study NCT05580575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily disposable toric soft contact lens
Description: Daily disposable toric soft contact lens
Study NCT05580575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monthly replacement toric daily wear soft contact lens
Description: Monthly replacement toric daily wear soft contact lens
Study NCT06533839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permanent colostomy
Description: A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
Study NCT06533839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent colostomy
Description: A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
Study NCT04798586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab (PF-06863135)
Description: BCMA-CD3 bispecific antibody